Navigation Links
Kosan Presents Updated Data on Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma at Ash
Date:12/8/2007

HAYWARD, Calif., Dec. 8 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented updated data from a dose-escalating Phase 1b clinical trial of Hsp90 inhibitor tanespimycin (KOS-953) in combination with bortezomib (Velcade(R)), showing durable antitumor activity and tolerability in patients with multiple myeloma who had previously progressed following treatment with multiple conventional therapies. The data presentation includes summary aggregate results from patients treated with all doses of Kosan's prior Cremophor-containing formulation and with Kosan's new injectable suspension formulation. Responses were seen across dose levels in the bortezomib-naive, pre-treated and refractory patients. Both formulations demonstrated activity, and the combination was manageable relative to safety, with no Grade 3 neurotoxicity to date. This finding supports the potential neuroprotective effect of tanespimycin. The data were presented on Saturday, December 8, 2007, by Paul Richardson, M.D., Department of Hematology, Dana Farber Cancer Center, Boston, MA, in a poster titled "Tanespimycin (T) + Bortezomib (BZ) in Multiple Myeloma (MM): Confirmation of the Recommended Dose Using a Novel Formulation," at the 2007 Annual Meeting of the American Society of Hematology (ASH).

"Tanespimycin continues to be of interest as a potential treatment for patients with multiple myeloma who have failed prior regimens due to its tolerability and potential for additive or synergistic activity with bortezomib," said Kenneth C. Anderson, M.D., Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, senior author on the poster. "The new injectable suspension formulation appears to be
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. Kosan Presents Phase 1 Data Showing Antitumor Activity and Safety Profile of Epothilone KOS-1584 at AACR/NCI/EORTC Meeting
6. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
7. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
8. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
9. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... 3, 2015  Encision Inc. (PK:ECIA), a medical device ... electrosurgical burns in minimally invasive surgery, today announced financial ... June 30, 2015. The Company posted quarterly ... loss of $213 thousand, or $(0.02) per share. These ... a net loss of $202 thousand, or $(0.02) per ...
(Date:8/2/2015)... -- Mandatory takeover offer for the ... the "Company") is pleased to announce the signing of ... Marijan Han žeković to acquire his 63.3% holding (equivalent ... Croatian listed pharmaceutical business.   Dechra is ... €51.4 million for the entire share capital on a ...
(Date:7/31/2015)... More than 1,500 substance abuse prevention and treatment specialists ... Indianapolis Aug. 2-6 for Community Anti-Drug Coalitions ... The week-long training, held at the JW Marriott, will ... biggest public health challenges – youth drug use. ... intensive training opportunity, offering more than 70 half-day and ...
Breaking Medicine Technology:Encision Reports First Quarter Fiscal Year 2016 Results 2Encision Reports First Quarter Fiscal Year 2016 Results 3Encision Reports First Quarter Fiscal Year 2016 Results 4Encision Reports First Quarter Fiscal Year 2016 Results 5Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 2Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 3Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 4Dechra to Acquire 63.3% Shareholding (£19.4m) in Genera d.d. Croatia 5Community Leaders From Across The Country Head To Indianapolis For CADCA 2015 Mid-Year Training Institute Aug. 2-6 2
... Immunomedics, Inc. (Nasdaq: IMMU ) , ... to treat cancer and other serious diseases, today ... Cancers Symposium showed that labetuzumab-SN-38, an antibody-drug conjugate, ... animal models as an effective new therapy. ...
... Fla., Jan. 19 A new approach to unblocking ... down time, lower costs and less risk overall, particularly ... the 21st annual International Symposium on Endovascular Therapy (ISET). ... over bypass surgery to open their blocked arteries. New ...
Cached Medicine Technology:Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 2Immunomedics Announces Preclinical Therapy Results of SN-38 Immunoconjugate for Colorectal Cancer 3Wrist Access Safer, Easier for Many Patients Undergoing Minimally Invasive Treatment of Blocked Heart Arteries 2
(Date:8/3/2015)... ... August 03, 2015 , ... A July 9 article from USA Today ... years, according to the American Dental Association. According to a study by the American ... 1.1 million in a single year to 2.2 million a year. Dentists and ADA ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... , ... August 03, 2015 , ... Constantin Vasilica, 48 ... by tissue injury caused by diabetes after many years of suffering and using medications ... and he didn’t want to ask for extra time off or wait longer hours ...
(Date:8/3/2015)... (PRWEB) , ... August 03, ... ... (EMSI), a leading provider of medical information, risk management and investigative services, ... evolution and direction toward focused, expert information solutions that improve business outcomes ...
(Date:8/3/2015)... ... August 03, 2015 , ... Recent reports by the American Medical ... least once in their lives. Often time, low back and sciatic pain can happen ... only be managed clinically with powerful pain medication or spinal surgery. Dynamic Health ...
Breaking Medicine News(10 mins):Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 2Health News:Los Angeles Periodontists Comment on Rising Dental Emergency Room Trips 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 2Health News:Chinese Health Care Provider Heshoutang Now Give Patients Complimentary Online Healing Options 3Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Dynamic Health Care in Louisville, KY, Offers a New and Cutting-Edge Therapy for Low Back & Leg Pain Sufferers 2
... ... for the American Water Works Association’s (AWWA) 2010 Annual Conference & Exposition (ACE10), June ... ... American Water Works Association’s (AWWA) 2010 Annual Conference & Exposition (ACE10), June 20-24, in ...
... ... Services, CGI Federal, first contacted the Metropolitan Washington, DC Chapter of the Cystic ... his 2-month old daughter Melissa and 3-year old son Matthew had recently been ... children’s diagnosis, the average age of survival for a child with CF was ...
... ... is pleased to announce a new research grant program to fund investigations related to ... ... The American Orthopaedic Society for Sports Medicine (AOSSM), in partnership with Genzyme Biosurgery, ...
... ... is extending its reach to provide expanded resources, seminars, presentations and E-learning opportunities in ... Belleville, ... individuals on skin integrity, seating and positioning, as well as wheelchair cushion and medical ...
... , ... fewer employer sponsored plans and overwhelmed state agencies are possible causes for the increase ... ... families and individuals requested health insurance quotes from HealthInsuranceSort. The need for individual ...
... ... lead in water technology. , ... California (PRWEB) February 25, 2010 -- In a country with few natural resources, Israel is ... industry to help it weather the effects of the global meltdown., , ,Mouli Cohen, longtime ...
Cached Medicine News:Health News:AWWA Announces ACE10 Speakers 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 2Health News:Cystic Fibrosis Foundation Awards CGI Corporation of the Year 3Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 2Health News:New Osteoarthritis Research Grant Program Initiated by AOSSM and Genzyme Biosurgery 3Health News:The ROHO Institute Announces Expansion of Continuing Education Programs 2Health News:The ROHO Institute Announces Expansion of Continuing Education Programs 3Health News:The ROHO Institute Announces Expansion of Continuing Education Programs 4Health News:HealthInsuranceSort.com Provides Record Number of Health Insurance Quotes in 2009 2Health News:Mouli Cohen on Innovating Israeli Water Technology 2
... Ultralight Jarrod Goggles have set the ... Nonslip soft silicone saddle nose bridge. ... better and lasts longer. Adjustable elastic ... without breakable plastic strap clips. 0.75 ...
QualCraft™ Radiation-Reducing Eyewear is 50% lighter than other protective eyewear. Manufactured for the ultimate combination of comfort, function, and protection....
QualCraft™ Radiation Protection Eyewear providex maximum comfort and eye protection! Lenses made of 0.75 mm leaded glass. Side shields of 0.30 mm leaded acrylic help seal out scatter radiation ...
Portable shields for your safety and convenience....
Medicine Products: